Late-Breaking Partnering for Cures Addition: Hamburg and Woodcock to Discuss Drug Development in the Age of Targeted Therapy

We are excited to share with you a late-breaking addition to the already stellar Partnering for Cures program! A new plenary session now features News from FDA: Drug Development in the Age of Targeted Therapy.On December 14, 2010, FDA Commissioner Dr. Margaret Hamburg and Director of the Center for Drug Evaluation and Research Dr. Janet Woodcock will discuss how advances in science and technology, including genomics, offer exciting new opportunities to transform the drug development and review process. They will address how academia, companies, and FDA can speed the development of targeted treatments for cancer and other devastating illnesses, including innovative trial designs and regulatory policies.

With less than two weeks until Partnering for Cures, we have plenty to look forward to:

• a dynamic program (12 panels and four plenary sessions) with an exemplary speaker roster.
• a customized partnering system that eases the process of finding the right contacts and establishing meaningful relationships (already live and active!).
• a new addition to the program, the Expert Consultations component allows participants to schedule free, one-on-one consultations with scientific, technical, and financial leaders.
• an innovator presentation track featuring 31 case studies of cross-sector collaborations.
• focused networking opportunities according to specific therapeutic affinity areas.

Register now and benefit from productive collisions with nontraditional allies from across sectors of medical research.